Nashville-based ophthalmic disease management company Harrow has announced leadership changes at its subsidiary, ImprimisRx. Frank Mullery has been appointed as CEO and Bridseida Cruz has been appointed as head of quality. 

Frank Mullery.png

Frank Mullery, CEO ImprimisRx.

Mullery is a senior executive with more than 20 years of leadership experience in the health care and pharmaceutical industries. Most recently, he served as president of Sintetica US, where he spearheaded the creation of the company’s U.S. subsidiary while launching its first five sterile injectable products. 

Dr. Divya Shroff

Dr. Divya Shroff, vice chair of clinical affairs and associate professor of Internal Medicine, Thomas F. Frist, Jr. College of Medicine at Belmont University

Recommended for you